Maximizing Outcomes in Treating Acute Migraine
Trial details
- Registry ID
- NCT03896009
- Phase
- Phase 3
The FDA approved Meloxicam on 13 Apr 2000.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Maximizing Outcomes in Treating Acute MigraineNCT03896009 | AXSM | Phase 3 | Completed | 2019-12-10Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2000-04-13Day | Meloxicam | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020938", "applicant_as_listed_by_fda": "BOEHRINGER INGELHEIM", "brand_names": ["MOBIC"], "active_ingredients": ["MELOXICAM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20000413", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |